MOLECULAR BASIS OF β2-MICROGLOBULIN AMYLOIDOSIS



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Beta2-microglobulin am yloidosis (Aβ2M -amyloidosis) - is complication of chronic hemodialysis, resulting from accumulation of amyloid deposits in the patient’s tissues. The major component of the amyloid is presented by beta2-microglobulin (β2M) fibrils. Normally β2M is excreted by kidneys, but in patients with end-stage renal disease β2M concentration is continuously increased due to impaired renal excretion. High β2M serum concentration is necessary but not sufficient for the development of Aβ2M-amyloidosis. Other factors resulting in the β2M polymerization and the deposition of amyloid fibrils are not clear, and in present time they the subject of in vivo and in vitro studies. Despite the clinical importance and fairly high incidence of this disease, in Russian literature these issue is gaining very little attention. In particular, we do not know works, descriding in detail the molecular aspect of the Aß2M amyloidosis. In this review, we have attempted to summarize the literature data and the results obtained in our laboratory regarding to the biochemical processes underlying the abnormal fibrilogenesis of β2M. Individually it is written about the problems of in vitro simulation, diagnosis, and immunological aspects of the disease. The clinical manifestations of Aβ2M amyloidosis are briefly summarized.

Full Text

Restricted Access

About the authors

D S Polyakov

Institute of Experimental Medicine of the North-West Branch of the Russian Academy of Medical Sciences

Email: ravendoctor@mail.ru
St.-Petersburg, Russia

M M Shavlovsky

Institute of Experimental Medicine of the North-West Branch of the Russian Academy of Medical Sciences

St.-Petersburg, Russia

References

  1. Massry S. G., Coburn J. W. Guideline 10. β2-microglobulin amyloidosis. Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease // Amer. J. of Kidney Diseases.- 2003.- Vol. 42, Suppl. 3.- Р. 1-202.
  2. Zingraff J. J., Noel L. H., Bardin T. et al. Beta2-microglobulin amyloidosis in chronic renal failure // N. Engl. J. Med.- 1990.- Vol. 323.- Р. 1070-1071.
  3. Moriniere P., Marie A., el Esper N. et al. Destructive spondyloarthropathy with beta 2-microglobulin amyloid deposits in a uremic patient before chronic hemodialysis // Nephron.- 1991.- Vol. 59.- Р. 654-657.
  4. Goldsby R.A., Kindt T. J., Osborne B.A. Major histocompatibility complex // Kuby Immunology / ed. W. H. Freeman.- 2007.- Р. 166-178.
  5. Bjorkman P. J., Saper M. A., Samraoui B. et al. Structure of the human class-I histocompatibility antigen, HLA-A2 // Nature.- 1987.- Vol. 329.- Р. 506- 512.
  6. Шило В. Ю., Денисов А. Ю. Позднее осложнение программного гемодиализа: бета 2-микроглобулиновый амилоидоз // Врач: Ежемесячный научно-практический и публицистический журнал.- 2002.- № 6.- Р. 7-12.
  7. Maruyama H., Gejyo F., Arakawa M. Clinical studies of destructive spondyloarthropathy in long-term hemodialysis patients // Nephron.- 1992.- Vol. 61.- Р. 37-44.
  8. Gejyo F., Narita I. Current clinical and pathogenetic understanding of b2-m amyloidosis in long-term haemodialysis patients // Nephrology.- 2003.- Vol. 8.- Р. S45-S49.
  9. Davison A. M. B2-microglobulin and amyloidosis: who is at risk? // Nephrol. Dial. Transplant.- 1995.- Vol. 10.- Р. 48-51.
  10. Berggard I., Beam A. G. Isolation and properties of a low molecular weight B2-globulin occurring in human biological fluids // J. Biol. Chem.- 1968.- Vol. 243.- Р. 4095-4103.
  11. Warren D. J., Otieno L. S. Carpal tunnel syndrome in patients on intermittent haemodialysis // Postgrad. Med. J.- 1975.- Vol. 51.- Р. 450-452.
  12. Kenzora J. E. Dialysis carpal tunnel syndrome // Orthopedics.- 1978.- Vol. 1.- Р. 195-203.
  13. Jain V. K., Cestero R. V., Baum J. Carpal tunnel syndrome in patients undergoing maintenance HD // JAMA.-1979.- VT 242.- Р. 2868-2869.
  14. Assenat H., Calemard E., Charra B. et al. Hemodialyse, syndrome du canal carpien et substance amyloid // Nouv. Presse. Med.- 1980.- Vol. 24.- Р. 1715.
  15. Charra B., Calemard E., Uzan M. et al. Carpal tunnel syndrome, shoulder pain and amyloid deposits in longterm hemodialysis patients // Proc. Eur. Dial. Transpl. Assoc.- 1984.- Vol. 21.- Р. 291-295.
  16. Kuntz D., Naveau B., Bardin T. et al. Destructive spondylarthlopaty in hemodialyzed patients. A new syndrome // Arthritis Rheum.- 1984.- Vol. 27.- Р. 369-375.
  17. Gejyo F., Yamada T., Odani S. et al. A new form of amyloid protein associated with chronic hemodialysis was identified as b2-microglobulin // Biochem. Biophys. Res. Commun.- 1985.- Vol. 129.- Р. 701-706.
  18. Heegaard N. H. β2-microglobulin: from physiology to amyloidosis // Amyloid.- 2009.- Vol. 16.- Р. 151-173.
  19. Okon M., Bray P., Vucelic D. NMR assignments and secondary structure of human beta 2-microglobulin in solution // Biochemistry.- 1992.- Vol. 31.- Р. 8906-8915.
  20. Chiu I., Davis D., Strominger J. Trafficking of spontaneously endocytosed MHC proteins // Proc. Natl. Acad. Sci. USA.- 1999.- Vol. 96, № 24.- P. 13944-13949.
  21. Drakesmith H., Townsend A. The structure and function of HFE // Bioessays.- 2000.- Vol. 22.- Р. 595-598
  22. Waheed A., Grubb J. H., Zhou X. Y. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis // Proc. Natl. Acad. Sci. U. S. A.- 2002.- Vol. 99.- Р. 3117-3122.
  23. Leitner K., Ellinger A., Zimmer K. P. et al. Localization of b2-microglobulin in the term villous syncytiotrophoblast // Histochem Cell Biol.- 2002.- Vol. 117.- Р. 187-193.
  24. Kim J. Y., Park S. C., Lee J. K. et al. Novel antibacterial activity of ß(2)-microglobulin in human amniotic fluid // PLoS One.- 2012.- Vol. 7 (11).- Р. e47642.
  25. Miyata T., Inagi R., Iida Y. et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1 // J. Clin. Invest.- 1994.- Vol. 93.- Р. 521-528.
  26. Gorevic P. D., Casey T. T., Stone W. J. et al. Beta-2 microglobulin is an amyloidogenic protein in man // J. Clin. Invest.- 1985.- Vol. 76.- Р. 2425-2429.
  27. Gorevic P. D., Munoz P. C., Casey T. T. et al. Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients on chronic haemodialysis // Proc. Natl. Acad. Sci. USA.- 1986.- Vol. 83.- Р. 7908-7912.
  28. Hall P. W., Ricanati E. S., Vacca C. V. Characterization of human beta2-microglobulin by isoelectric focusing // Clin. Chim. Acta.- 1977.- Vol. 77.- Р. 37-42.
  29. Argiles A., Garcia-Garcia M., Derancourt J. et al. Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits // Kidney Int.- 1995.- Vol. 48.- Р. 397-405.
  30. Linke R. P., Hampl H., Lobeck H. et al. Lysine-specific cleavage of beta2-microglobulin in amyloid deposits associated with haemodialysis // Kidney Int.- 1989.- Vol. 36.- Р. 675-681.
  31. Поляков Д. С., Тотолян Арег А., Шавловский М. М. Получение природного бета2-микроглобулина человека // Молекулярная медицина.- 2010.- Vol. 6.- Р. 39-43.
  32. Miyata T., Oda O., Inagi R. et al. Beta 2-microglobulin modified with advanced glycation end products is a major component of hemodialysisassociated amyloidosis // J. Clin. Invest.- 1993.- Vol. 92.- Р. 1243-1252.
  33. Niwa T., Miyazaki S., Katsuzaki T. et al. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis // Kidney Int.- 1995.- Vol. 48.- Р. 771-778.
  34. Niwa T., Sato M., Katsuzaki T. et al. Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis // Kidney Int.- 1996.- Vol. 50.- Р. 1303-1309.
  35. Miyata T., Sprague S. M. Advanced glycation of b2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis // Nephrol. Dial. Transplant.- 1996.- Vol. 11.- Р. 86-90.
  36. Odani H., Oyama R., Titani K. et al. Purificarion and complete amino acid sequence of novel beta 2-microglobulin // Biochem. Biophys. Res. Commun.- 1990.- Vol. 168.- Р. 1223-1229.
  37. Stoppini M., Mangione P., Monti M. et al. of beta2-microglobulin amyloid fibrils // Biochim. Biophys. Acta.- 2005.- Vol. 1753.- Р. 23-33.
  38. Linke R. P., Hampl H., Bartel-Schwarze S., Eulitz M. Beta2-microglobulin, different fragments and polymers thereof in synovial amyloid in longterm haemodialysis // Biol. Chem.- 1987.- Vol. 368.- Р. 137-144.
  39. Stoppini M., Arcidiaco P., Mangione P. et al. Detection of fragments of beta2-microglobulin in amyloid fibrils // Kidney Int.- 2000.- Vol. 57.- Р. 349-350.
  40. Bellotti V., Stoppini M., Mangione P. et al. Beta2-microglobulin can be refolded into a native state from ex vivo amyloid fibrils // Eur. J. Biochem.- 1998.- Vol. 258.- Р. 61-67
  41. Bellotti V., Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases // Current Opinion in Structural Biology.- 2008.- Vol. 18.- Р. 771-779.
  42. Esposito G., Michelutti R., Verdone G. et al. Removal of the N-terminal hexapeptide from human beta2-microglobulin facilitates protein aggregation and fibril formation // Protein Sci.- 2000.- Vol. 9.- Р. 831-845.
  43. Inoue S., Kuroiwa M., Kisilevsky R. Basement membranes, microfibrils and beta amyloid fibrillogenesis in Alzheimer s disease: high resolution ultrastructural findings // Brain Res Brain Res Rev.- 1999.- Vol. 29.- Р. 218-231.
  44. Pepys M. B., Herbert J., Hutchinson W. L. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis // Nature.- 2002.- Vol. 417.- Р. 254-259.
  45. Jakobson D. J., Eidelman L. A., Worner T. M. et al. Evaluation of changes in forgoing life-sustaining treatment in Israeli ICU patients // Chest.- 2004.- Vol. 126 (6).- Р. 1969-1973.
  46. Tennent G. A., Lovat L. B., Pepys M. B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis // Proc. Natl. Acad. Sci. U.S.A.- 1995.- Vol. 92.- Р. 4299-4303.
  47. Kisilevsky R., Ancsin J. B., Szarek W. A., Petanceska S. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications // Amyloid.- 2007.- Vol. 14.- Р. 21-32.
  48. Ohashi K., Kawai R., Hara M. et al. Increased matrix metalloproteinases as possible cause of osseoarticular tissue destruction in long-term haemodialysis and beta 2-microglobulin amyloidosis // Virchows Arch.- 1996.- Vol. 428.- Р. 37-46.
  49. Brancaccio D., Gallieni M., Niwa T. et al. Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis // J. Nephrol.- 2000.- Vol. 13.- Р. 129-136.
  50. Fukunishi S., Yoh K., Kamae S., Yoshiya S. Beta 2-microglobulin amyloid deposit in HLA-B27 transgenic rats // Mod. Rheumatol.- 2007.- Vol. 17.- Р. 380-384.
  51. Relini A., Canale C., De Stefano S. et al. Esposito G. Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis // J. Biol. Chem.- 2006.- Vol. 281.- Р. 16521-16529.
  52. Garcia-Garcia M., Mourad G., Durfort M. et al. Vascular involvement and cell damage in experimental AA and clinical beta(2)-microglobulin amyloidosis // Nephrol Dial Transplant.- 2002.- Vol. 8.- Р. 1450-1456.
  53. Ancsin J. B. Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit // Amyloid.- 2003.- Vol. 10.- Р. 67-79.
  54. Yamamoto S., Yamaguchi I., Hasegawa K. et al. Glycosaminoglycans enhance the trifluoroethanol-induced extension of beta2-microglobulinrelated amyloid fibrils at a neutral pH // J. Am. Soc. Nephrol.- 2004.- Vol. 15.- Р. 126-133.
  55. Tan S. Y., Irish A., Winearls C. G. et al. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology // Kidney Int.- 1996.- Vol. 50.- Р. 282-289.
  56. Yamaguchi I., Suda H., Tsuzuike N. et al. Glycosaminoglycan and proteoglycan inhibit the depolymerization of beta2-microglobulin amyloid fib rils in vitro // Kidney Int.- 2003.- Vol. 64.- Р. 1080-1088.
  57. Myers S. L., Jones S., Jahn T. R. et al. A systematic study of the effect of physiological factors on beta2-microglobulin amyloid formation at neu tral pH // Biochemistry. - 2006.- Vol. 45.- Р. 2311-2321.
  58. Cong L., Sawaya M., Eisenberg D. β2-microglobulin forms three-dimensional domain-swapped amyloid fibrils with disulfide linkeges // Nature.- 2011.- Vol. 18, № 1.- Р. 49-56.
  59. J. Knaus, M. Morillas, W. Swietnicki, M. Malone, W. Surewic, V. Yee1. Crystal structure of the human prion proteinreveals a mechanism for oligomerization // Nature Structure Biology.- 2001.- Vol. 8, № 9.- Р. 770-774.
  60. Kusumoto Y., Lomakin A., Teplow D. B., Benedek G. B. Temperature dependence of amyloid beta-protein fibrillization // Proc. Natl. Acad. Sci.-1998.- Vol. 95.- Р. 12277-12282.
  61. Walsh D. M., Hartley D. M., Kusumoto Y. et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates // J. Biol. Chem.- 1999.- Vol. 274.- Р. 25945-25952.
  62. White H. E., Hodgkinson J. L., Jahn T. R. et al. Globular Tetramers of ß2-microglobulin Assemble into Elaborate Amyloid Fibrils // J. Mol. Biol.- 2009.- Vol. 389, № 1.- Р. 48-58.
  63. Pal-Gabor H., Gombos L., Micsonai A. et al. Mechanism of lysophosphatidic acid-induced amyloid fibril formation of beta(2)-microglobulin in vitro under physiological conditions // Biochemistry.- 2009.- Vol. 48.- Р. 5689-5699.
  64. McParland V. J., Kad N. M., Kalverda A. P. et al. Partially unfolded states of ß2-microglobulin and amyloid formation in vitro // Biochemistry.- 2000.- Vol. 39.- Р. 8735-8746.
  65. Radford S. E., Gosal W. S., Platt G. W. Towards an understanding of the structural molecular mechanism of ß2-micro globulin amyloid formation in vitro // Biochim. Biophys. Acta.- 2005.- Vol. 1753.- Р. 51-63.
  66. Chiba T., Hagihara Y., Higurashi T. et al. Amyloid fibril formation in the context of full-length protein. Effects of proline mutations on the amyloid fibril formation of B2-microglobulin // J. Biol. Chem.- 2003.- Vol. 278.- Р. 47016-47024.
  67. Kihara M., Chatani E., Sakai M. et al. Seeding-dependent maturation of ß2-microglobulin amyloid fibrils at neutral pH // J. Biol. Chem.- 2005.- Vol. 280.- Р. 12012-12018.
  68. Ventura S., Villaverde A. Protein quality in bacterial inclusion bodies // Trends Biotechnol.- 2006.- Vol. 24.- Р. 179-185.
  69. Поляков Д. С., Грудинина Н. А., Соловьев К. В. и др. Получение рекомбинантного β2-микроглобулина человека и его фибриллогенез при низких и нейтральных значениях рН // Молекулярная медицина.- 2011.- № 2.- С. 36-39.
  70. Поляков Д. С., Грудинина Н. А., Соловьев К. В. и др. Бета-2-микроглобулиновый амилоидоз: фибриллогенез природного и рекомбинантных бета-2-микроглобулинов человека // Медицинский академический журнал.- 2010.- Т. 10, № 2.- С. 40-49.
  71. Lonnemann G., Koch K. β2-Microglobulin Amyloidosis: Effect of Ultrapure Dialysate and Type of Dialyzer Membrane // Journal of the American Society of Nephrology.- 2002.- Vol. 13, Suppl. 1.- Р. 72-77.
  72. Relini A., De Stefano S., Torrassa S. et al. Heparin strongly enhances the formation of beta2-microglobulin amyloid fibrils in the presence of type I collagen // J. Biol. Chem.- 2008.- Vol. 283.- Р. 4912-4920.
  73. Uji Y., Motomiya Y., Ando Y. Effect of heparin on conformation of the ß2-microglobulin molecule // Ther. Apher Dial.- 2012.- Vol. 16 (2).- Р. 159-162.
  74. Артеева И. В., Егоров В. В., Горшков А. Н. и др. Моделирование олигомеризации и фибриллогенез мутантных форм бета-2 микроглобулина // Медицинский академический журнал.- 2013.- Т. 13, № 4.- С. 92-100.
  75. Solovyov K. V., Polyakov D. S., Grudinina N. A. et al. Expression in E.coli and purification of the fibrillogenic fusion proteins TTR-SFGFP and ß2M-SFGFP // Preparative biochemistry and biotechnology.- 2011.- № 41.- P. 1-13.
  76. Levine H. III. Thioflavine T interaction with synthetic Alzheimer s disease b-amyloid peptides: detection amyloid aggregation in solution // Prot. Sci.- 1993.- Vol. 3, № 2.- Р. 404-410.
  77. Mangione P. P., Esposito G., Relini A. et al. Structure, folding dynamics, nd amyloidogenesis of D76N ß2-microglobulin: roles of shear flow, hydrophobic surfaces, and a-crystallin // J Biol Chem. - 2013.- Vol. 288 (43).- Р. 30917-30930.
  78. Sprague S. M., Moe S. M. Clinical manifestations and pathogenesis of dialysis-related amyloidosis // Semin. Dial.- 1996.- Vol. 9.- Р. 360-369.
  79. Garbar C., Jadoul M., Noel H., van Ypersele de Strihou C. Histological characteristics of sternoclavicular b2-microglobulin amyloidosis and clues for its histogenesis // Kidney Int.- 1999.- Vol. 55.- Р. 1983-1990.
  80. Sanchez R., Praga M., Salas J. J. R. et al. Compressive myelopathy due to dialysis-associated amyloidosis // Nephron.- 1993.- Vol. 65.- Р. 463-465.
  81. Deforges-Lasseur C., Combe C., Cernier A. et al. Destructive spondyloarthropathy presenting with progressive paraplegia in a dialysis patient. Recovery after surgical spinal cord decompression and parathyroidectomy // Nephrol. Dial. Transplant.- 1993.- Vol. 8.- Р. 180-184.
  82. Danesh F.R., Klinkmann J., Yokoo H., Ivanovich P. Fatal cervical spondyloarthropathy in a hemodialysis patient with systemic deposition of β2-microglobulin amyloid // Am. J. Kidney Dis.- 1999.- Vol. 33.- Р. 563-566.
  83. Di Raimondo C. R., Casey T. T., Di Raimondo C. V., Stone W. J. Pathologic fractures associated with idiopathic amyloidosis of bone in chronic hemodialysis patients // Nephron.- 1986.- Vol. 43.- Р. 22-27.
  84. Bardin T., Zingraff J., Shirahama T. et al. Hemodialysis-associated amyloidosis and b2-microglobulin. Clinical and immnohistochemical study // Am. J. Med.- 1987.- Vol. 83.- Р. 419-424.
  85. Uenotsuchi T., Imafuku S., Nagata M. et al. Cutaneous and lingual papules as a sign of beta2microglobulin-derived amyloidosis in a longterm hemodialysis patient // Eur. J. Dermatol.- 2003.- Vol. 13.- Р. 393-395.
  86. Sato K. C., Kumakiri M., Koizumi H. et al. Lichenoid skin lesions as a sign of beta 2-microglobulin-induced amyloidosis in a long-term haemodialysis patient // Br. J. Dermatol.- 1993.- Vol. 128.- Р. 686-689
  87. Albers S. E., Fenske N. А., Glass L. F. et al. Atypical beta 2-microglobulin amyloidosis following short-term hemodialysis // Am. J. Dermatopathol.- 1994.- Vol. 16.- Р. 179-184
  88. Shimizu S., Yasui C., Yasukawa K. et al. Subcutaneous nodules on the buttocks as a manifestation of dialysis-related amyloidosis: a clinicopathological entity? // Br. J. Dermatol.- 2003.- Vol. 149.- Р. 400-404.
  89. Gal R., Korzets A., Schwartz A. et al. Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Report of seven cases and review of the literature // Arch. Pathol. Lab. Med.- 1994.- Vol. 118.- Р. 718-721.
  90. Takayama F., Miyazaki S., Morita T. et al. Dialysis related amyloidosis of the heart in long-term homodialysis patients // Kidney Int.- 2001.- Vol. 59, suppl. 78.- Р. S172- S176.
  91. Lopez-Davia J., Vilata J. J., Hernandez-Bel P. et al. Deposits of Amyloid (Beta-2 Microglobulin Type) in the Tongue // Amer. J. of Dermatopathology.- 2013.- April 4.
  92. Valleix S., Gillmore J. D., Bridoux F. et al. Hereditary systemic amyloidosis due to Asp76Asn variant ß2-microglobulin // N. Engl. J. Med.- 2012.- Vol. 366 (24).- Р. 2276-2283.
  93. Rysava R., Merta M., Tesar V. et al. Mediators of amyloidogenesis and cytokines in dialysis-related amyloidosis // Cas. Lek. Cesk.- 2002.- Vol. 26.- Р. 244-247.
  94. Поляков Д. С., Домашенко О. М., Белобородов П. В. и др. Содержание цитокинов в плазме крови больных, находящихся на хроническом гемодиализе // Медицинская иммунология.- 2011.- Vol. 2-3.- Р. 211-218.
  95. Herbelin A., Urena P., Nguyen A. T. et al. Elevated circulating levels of interleukin-6 in patients with chronic renal failure // Kidney Int.- 1991.- Vol. 39.- Р. 954-960.
  96. Pereira B. J., Shapiro L., King A. J. et al. Plasma levels of IL-1 beta, TNF-α and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients // Kidney Int.- 1994.- Vol. 45.- Р. 890-896.
  97. Cavaillon J. M., Poignet J. L., Fitting C., Delons S. Serum interleukin-6 in long-term hemodialyzed patients // Nephron.- 1992.- Vol. 60.- Р. 307-313.
  98. Libetta C., De Nicola L., Rampino T. et al. Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation // Kidney Int.- 1996.- Vol. 49.- Р. 506-511.
  99. Pereira B. J., Snodgrass B. R., Hogan P. J., King A. J. Diffusive and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes // Kidney Int.- 1995.- Vol. 47.- Р. 603-610.
  100. Descamps-Latscha B., Herbelin A., Nguyen A. T. et al. Balance between IL-1 beta, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes // J. Immunol.- 1995.- Vol. 154.- Р. 882-892.
  101. Kaizu Y., Kimura M., Yoneyama T. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients // Am J Kidney Dis.- 1998.- Vol. 31.- Р. 93-100.
  102. Kimmel P. L., Phillips T. M., Simmens S. J. Immunologic function and survival in hemodialysis patients // Kidney Int.- 1998.- Vol. 54.- Р. 236-244.
  103. Moe S. M., Sprague S. M. β2-microglobulin induces calcium efflux from cultured neonatal mouse calvariae // Am. J. Physiol.- 1992.- Vol. 263.- Р. F540- F545.
  104. Gowen M., Wood D. D., Ihrie E. J. et al. An interleukin-1 like factor stimulates bone resorption in vitro // Nature.- 1983.- Vol. 306.- Р. 378-380.
  105. Horowitz M. C. Cytokines and estrogen in bone. Anti-osteoporotic effects // Science.- 1993.- Vol. 260.- Р. 626-627.
  106. Ishimi Y., Miyaura C., Jin C. H. et al. IL-6 is produced by osteoblasts and induces bone resorption // J. Immunol.- 1990.- Vol. 145.- Р. 3297-3303.
  107. Kurihara N., Bertolini D., Suda T. et al. IL-6 stimulated osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release // J. Immunol.- 1990.- Vol. 144.- Р. 4226-4230.
  108. Balant E., Marshall C. F., Sprague S. M. Role of interleukin-6 in b2-microglobulin-induced bone mineral dissolution // Kidney Int.- 2000.- Vol. 57.- Р. 1599-1607.
  109. Menaa C., Esser E., Sprague S. M. β2-microglobulin stimulates osteoclast formation // Kidney International. 2008.- Vol. 73.- Р. 1275-1281.
  110. McGrath L. T., Douglas A. F., McClean E. et al. Oxidative stress and erythrocyte membrane fluidity in patients undergoing regular dialysis // Clin Chim Acta.- 1995.- Vol. 235.- Р. 179-188.
  111. Loughrey C. M., Young I. S., Lightbody J. H. et al. Oxidative stress in haemodialysis // QJM87.- 1994.- Р. 679-683.
  112. Miyata T., van Ypersele de Strihou C., Kurokawa K., Baynes J. W. Alterations in nonenzymatic biochemistry in uremia: origin and significance of «carbonyl stress» in long-term uremic complications // Kidney Int.- 1999.- Vol. 55.- Р. 389-399.
  113. Odetti P., Cosso L., Pronzato M. A. et al. Plasma advanced glycosylation end-products in maintenance haemodialysis patients // Nephrol. Dial. Transplant.- 1995.- Vol. 10, № 11.- Р. 2110-2113.
  114. Sheikh-Hamad D., Ayus J. C. The patient with a clotted PTFE graft developing fever // Nephrol. Dial. Transplant.- 1998.- Vol. 13.- Р. 2392-2393.
  115. Palestro C. J., Vega A., Kim C. K. et al. Indium-111-labeled leukocyte scintigraphy in hemodialysis access-site infection // J. Nucl. Med.- 1990.- Vol. 31.- Р. 319-324.
  116. Naugle K., Darby M. L., Bauman D. B. et al. The oral health status of individuals on renal dialysis // Ann. Periodontol.- 1998.- Vol. 3.- Р. 197-205.
  117. Varela M. P., Kimmel P. L., Phillips T. M. Biocompatibility of hemodialysis membranes: interrelations between plasma complement and cytokine levels // Blood Purif.- 2001.- Vol. 19.- Р. 370-379.
  118. Hughes R. D. Review of methods to remove protein-bound substances in liver failure // Int. J. Artif. Org.- 2002.- Vol. 25.- Р. 911-917.
  119. De Smet R., Van Kaer J., van Vlem B. Toxicity of free p-cresol: a prospective and cross-sectional analysis // Clin Chem.- 2003.- Vol. 49.- Р. 470-478.
  120. Jacobs P., Glorieux G., Vanholder R. Interleukin/cytokine profiles in haemodialysis and in continuous peritoneal dialysis // Nephrol. Dial. Transplant.- 2004.- Vol. 19, Suppl. 5.- Р. v41-v45.
  121. Jadoul M., Garbar C., Noel H. et al. Histological prevalence of β2-microglobulin amyloidosis in hemodialysis: a prospective postmortem study // Kidney Int.- 1997.- Vol. 51.- Р. 1928-1932.
  122. Ohashi K., Hara M., Kawai R. et al. Cervical discs are most susceptible to beta 2-microglobulin amyloid deposition in the vertebral column // Kidney Int.- 1992.- Vol. 41.- Р. 1646-1652.
  123. Ketteler M., Koch K. M., Floege J. Imaging techniques in the diagnosis of dialysis-related amyloidosis // Semin Dial.- 2001.- Vol. 14, № 2.- Р. 90-93.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Polyakov D.S., Shavlovsky M.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies